Appili To Begin Clinical Drug Trials

The first drug candidate of Appili Therapeutics, an anti-infective drug development company, has been cleared to begin clinical trials in both Canada and the U.S.
The Halifax company said in a press release today that the Food and Drug Administration in the U.S. has cleared the company’s IND application to conduct a clinical trial of its compound ATI-1501. Similarly, Health Canada has given the